ARPA-H launched Phase I awards under its BioStabilization Systems (BoSS) program to support room-temperature storage and shipping for cell-based biologics. The initiative will provide up to $87 million over four years, with a Reversible Ambient Temperature (RAB) team receiving up to $7.3 million spanning Draper, Likarda, Case Bioscience, CPSI Biotech, Fresenius Kabi, MiNK Therapeutics, and the University of Colorado.